Critical Survey: Synaptogenix (TAOX) & Its Rivals

Synaptogenix (NASDAQ:TAOX) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Synaptogenix to related businesses based on the strength of its dividends, analyst recommendations, earnings, institutional ownership, profitability, risk and valuation.

Profitability

This table compares Synaptogenix and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Synaptogenix	-2,153.97%	-128.51%	-97.54%
Synaptogenix Competitors	-2,381.29%	-218.58%	-15.77%

Valuation & Earnings

This table compares Synaptogenix and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Synaptogenix	$772,499.00	-$28.74 million	-0.64
Synaptogenix Competitors	$5.42 billion	$3.22 billion	550.73

Synaptogenix’s competitors have higher revenue and earnings than Synaptogenix. Synaptogenix is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings and target prices for Synaptogenix and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1	0	0	0	1.00
Synaptogenix Competitors	7782	13876	25770	1035	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 25.24%. Given Synaptogenix’s competitors stronger consensus rating and higher probable upside, analysts clearly believe Synaptogenix has less favorable growth aspects than its competitors.

Institutional and Insider Ownership

10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 2.7% of Synaptogenix shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Synaptogenix has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, Synaptogenix’s competitors have a beta of -3.66, indicating that their average share price is 466% less volatile than the S&P 500.

Summary

Synaptogenix competitors beat Synaptogenix on 10 of the 13 factors compared.

Synaptogenix Company Profile

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.